KALY Releases Update Highlighting Potential In $14 Billion COPD Treatment Market and Additional Pharmaceutical Markets
January 30 2019 - 12:57PM
InvestorsHub NewsWire
KALY Releases Update Highlighting
Potential In $14 Billion COPD Treatment Market and Additional
Pharmaceutical Markets
Dallas, Tx –
January 30, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today
released a corporate update that includes the latest on KALY’s
developments with Puration, Inc, (USOTC: PURA) (“PURA”) and Generex
Biotechnology, Inc. (OTCBB: GNBT), the company’s research on
treatments for Chronic Obstructive Pulmonary Disease (COPD),
and other updates. The comprehensive update is included in its
entirety below:
Overview
Kali-Extracts, Inc. (“KALY”) is a health and
wellness company set to generate revenue from its patented cannabis
extraction technology through overlapping go-to-market
strategies. KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. Similarly, KALY its patented cannabis
extraction technology to develop pharmaceutical products internally
and through partnerships.
Puration, Inc. (USOTC: PURA)
KALY has
licensed its extraction process to PURA for the production of
beverages. With over $1 million in trailing twelve-month
sales, PURA’s sales of EVERx CBD Sports Water are growing.
KALY is now working with PURA to formulate a 25 MG CBD formula for
a new CBD infused water product. Together, PURA and KALY have
signed over a $1 million agreement to produce CBD infused water for
Generex Biotechnology, Inc. (OTCBB: GNBT). The GNBT product
is expected to be on shelves soon.
Hemp4mula
KALY has
introduced its own line of CBD infused candies under the name
Hemp4mula. KALY has signed its first distribution agreement
for Hemp4mula gum and initiated the production of Hemp4mula
gummies. Hemp4mula gum will be on retail shelves soon and for
sale on line soon.
Pharmaceuticals
Prior to KALY’s
recent acquisition of NCM Biotech (NCM), NCM had conducted numerous
trials on various treatment applications of extracts derived from
their patented extraction process. KALY recently disclosed
having completed an in vitro genomics study to evaluate the impact
of its pharmaceutical grade cannabis extracts in combination with
other therapies on Chronic Obstructive Pulmonary
Disease (COPD) patients. Favorable results prompted the launch
of a physiological study whose results will be released later this
quarter. The World Health Organization estimates 65 million people
worldwide are afflicted with moderate to severe COPD and GlobalData
forecasts that the COPD treatment market will reach $14.1 billion
by 2025. Other tests for other diseases to include cancer,
have been conducted utilizing extracts from KALY’s patented
extraction process. Shareholders can expect to see results
from these various tests to be forthcoming soon in addition to next
steps to advance the various potential treatments to
production. KALY is actively working to develop partnerships
with established, brand name pharmaceutical companies, to
accelerate the further development of cannabis extract
treaments.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024